Steroids for Scars

  • Ioannis GoutosEmail author


Steroid administration is a popular adjunct to scar management with numerous reports in the literature appraising this modality in hypertrophic and keloid scars. A variety of administration modes have been described, including injectable, ointment and transdermal (tape) forms. The most popular and extensively studied modality at present is the intralesional injection of corticosteroids with recent trends in international management protocols advocating the combined administration with other modalities, including chemotherapeutic agents and lasers. The aim of this chapter is to review the literature regarding the different modalities of steroid administration as well as the pertinent evidence base in the management of hypertrophic and keloid scars.


Steroid Scar Keloid Hypertrophic Intralesional Extralesional Tape Laser Radiation 



I would like to acknowledge Dr. Osaid Alser and Miss Ruthann Fanstone for their helpful contributions and input into this piece of work.


  1. 1.
    Behrman HT, Goodman JJ. Skin complications of cortisone and ACTH therapy. JAMA. 1950;144(3):218–21.CrossRefGoogle Scholar
  2. 2.
    Baker BL, Whitaker WL. Interference with wound healing by the local action of adrenocortical steroids. Endocrinology. 1950;46(6):544–51.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Polson JS, et al. Keloid. Can Med Assoc J. 1951;65(5):447–9.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Conway H, Stark RB. ACTH in plastic surgery. Plast Reconstr Surg (1946). 1951;8(5):354–77.CrossRefGoogle Scholar
  5. 5.
    Goldman L, Thompson RG, Trice ER. Cortisone acetate in skin disease; local effect in the skin from topical application and local injection. AMA Arch Derm Syphilol. 1952;65(2):177–86.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Coste F, Piguet B, Civitte J, Degos R, Vial-Weissenbach V, Grupper C. Traitement de Chelloides par Injections Locales d’Hydrocortisone. Trans Soc Franc de Derm et de Syph Presse med. 1953;61:1157.Google Scholar
  7. 7.
    De Kleine EH. Observations on the effect of cortisone on wound healing and scar formation. Plast Reconstr Surg. 1954;88:429.Google Scholar
  8. 8.
    Hollander A. Intralesional injections of triamcinolone acetonide; a therapy for dermatoses. Antibiotic Med Clin Ther (New York). 1961;8:78–83.Google Scholar
  9. 9.
    Murray RD. Kenalog and the treatment of hypertrophied scars and keloids in Negroes and whites. Plast Reconstr Surg. 1963;31:275–80.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Maguire HC Jr. Treatment of keloids with triamcinolone acetonide injected intralesionally. JAMA. 1965;192:325–6.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Griffith BH. The treatment of keloids with triamcinolone acetonide. Plast Reconstr Surg. 1966;38(3):202–8.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Minkowitz F. Regression of massive keloid following partial excision and post-operative intralesional administration of triamcinolone. Br J Plast Surg. 1967;20(4):432–5.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Jalali M, Bayat A. Current use of steroids in management of abnormal raised skin scars. Surgeon. 2007;5(3):175–80.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    McMaster A, Ray DW. Drug insight: selective agonists and antagonists of the glucocorticoid receptor. Nat Clin Pract Endocrinol Metab. 2008;4(2):91–101.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Kang N, Sivakumar B, Sanders R, Nduka C, Gault D. Intra-lesional injections of collagenase are ineffective in the treatment of keloid and hypertrophic scars. J Plast Reconstr Aesthet Surg. 2006;59(7):693–9.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    McCoy BJ, Diegelmann RF, Cohen IK. In vitro inhibition of cell growth, collagen synthesis, and prolyl hydroxylase activity by triamcinolone acetonide. Proc Soc Exp Biol Med. 1980;163(2):216–22.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Ogawa R. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. Int J Mol Sci. 2017;18(3):E606.CrossRefGoogle Scholar
  18. 18.
    Lawrence WT. In search of the optimal treatment of keloids: report of a series and a review of the literature. Ann Plast Surg. 1991;27(2):164–78.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Doggrell SA. Triamcinolone: new and old indications. Expert Opin Pharmacother. 2001;2(7):1177–86.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Lucky AW. Principles of the use of glucocorticosteroids in the growing child. Pediatr Dermatol. 1984;1:226–35.PubMedCrossRefGoogle Scholar
  21. 21.
    Grumbine N, Dobrowolski C, Bernstein A. Retrospective evaluation of postoperative intralesional steroid injections on wound healing. J Foot Ankle Surg. 1998;37(2):135–44. discussion 74.PubMedCrossRefGoogle Scholar
  22. 22.
    Brissett AE, Sherris DA. Scar contractures, hypertrophic scars, and keloids. Facial Plast Surg. 2001;17(4):263–72.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Kill J. Kleoids treated with topical injections of triamcinolone acetonide (Kenalog). Scand J Plast Reconsrt Surg. 1977;11:169–72.Google Scholar
  24. 24.
    Fredman R, Tenenhaus M. Cushing’s syndrome after intralesional triamcinolone acetonide: a systematic review of the literature and multinational survey. Burns. 2013;39(4):549–57.PubMedCrossRefGoogle Scholar
  25. 25.
    Darzi MA, Chowdri NA, Kaul SK, Khan M. Evaluation of various methods of treating keloids and hypertrophic scars: a 10-year follow-up study. Br J Plast Surg. 1992;45(5):374–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Ogawa R, Akaishi S, Kuribayashi S, Miyashita T. Keloids and hypertrophic scars can now be cured completely: recent progress in our understanding of the pathogenesis of keloids and hypertrophic scars and the most promising current therapeutic strategy. J Nippon Med Sch. 2016;83(2):46–53.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Mustoe TA, Cooter RD, Gold MH, Hobbs FD, Ramelet AA, Shakespeare PG, et al. International clinical recommendations on scar management. Plast Reconstr Surg. 2002;110(2):560–71.CrossRefGoogle Scholar
  28. 28.
    Ardehali B, Nouraei SA, Van Dam H, Dex E, Wood S, Nduka C. Objective assessment of keloid scars with three-dimensional imaging: quantifying response to intralesional steroid therapy. Plast Reconstr Surg. 2007;119(2):556–61.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Kelly AP. Update on the management of keloids. Semin Cutan Med Surg. 2009;28(2):71–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Rutkowski D, Syed F, Matthews LC, Ray DW, McGrouther DA, Watson RE, et al. An abnormality in glucocorticoid receptor expression differentiates steroid responders from nonresponders in keloid disease. Br J Dermatol. 2015;173(3):690–700.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Gupta S, Sharma VK. Standard guidelines of care: keloids and hypertrophic scars. Indian J Dermatol Venereol Leprol. 2011;77(1):94–100.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Mandal A, Imran D. Painless steroid injections for hypertrophic scars and keloids. Br J Plast Surg. 2003;56(1):79.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Vallis CP. Intralesional injection of keloids and hypertrophic scars with the Dermo-Jet. Plast Reconstr Surg. 1967;40(3):255–62.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Ono N. Pain-free intralesional injection of triamcinolone for the treatment of keloid. Scand J Plast Reconstr Surg Hand Surg. 1999;33(1):89–91.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Ceilley RI, Babin RW. The combined use of cryosurgery and intralesional injections of suspensions of fluorinated adrenocorticosteroids for reducing keloids and hypertrophic scars. J Dermatol Surg Oncol. 1979;5(1):54–6.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Zuber TJ, DeWitt DE. Earlobe keloids. Am Fam Physician. 1994;49(8):1835–41.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Muneuchi G, Suzuki S, Onodera M, Ito O, Hata Y, Igawa HH. Long-term outcome of intralesional injection of triamcinolone acetonide for the treatment of keloid scars in Asian patients. Scand J Plast Reconstr Surg Hand Surg. 2006;40(2):111–6.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Boyadjiev C, Popchristova E, Mazgalova J. Histomorphologic changes in keloids treated with Kenacort. J Trauma. 1995;38(2):299–302.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Brown LA Jr, Pierce HE. Keloids: scar revision. J Dermatol Surg Oncol. 1986;12(1):51–6.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Barton RP. Auricular keloids: a simple method of management. Ann R Coll Surg Engl. 1978;60(4):324–5.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Donkor P. Head and neck keloid: treatment by core excision and delayed intralesional injection of steroid. J Oral Maxillofac Surg. 2007;65(7):1292–6.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Tang YW. Intra- and postoperative steroid injections for keloids and hypertrophic scars. Br J Plast Surg. 1992;45(5):371–3.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Golladay ES. Treatment of keloids by single intraoperative perilesional injection of repository steroid. South Med J. 1988;81(6):736–8.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Tripoli M, Cordova A, Melloni C, Zabbia G, Maggì F, Moschella F. The use of triamcinolone combined with surgery in major ear keloid treatment: a personal two stages approach. Eur J Plast Surg. 2015;38(3):205–10.CrossRefGoogle Scholar
  45. 45.
    Chowdri NA, Masarat M, Mattoo A, Darzi MA. Keloids and hypertrophic scars: results with intraoperative and serial postoperative corticosteroid injection therapy. Aust N Z J Surg. 1999;69(9):655–9.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Park TH, Seo SW, Kim JK, Chang CH. Clinical characteristics of facial keloids treated with surgical excision followed by intra- and postoperative intralesional steroid injections. Aesthetic Plast Surg. 2012;36(1):169–73.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Rosen DJ, Patel MK, Freeman K, Weiss PR. A primary protocol for the management of ear keloids: results of excision combined with intraoperative and postoperative steroid injections. Plast Reconstr Surg. 2007;120(5):1395–400.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Moustafa MFH, Abdel-Fattah AMA. Keloids of the ear lobes in Egypt: their rarity in childhood and their treatment. Br J Plast Surg. 1976;29:59.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Kauh YC, Rouda S, Mondragon G, Tokarek R, di Leonardo M, Tuan RS, et al. Major suppression of pro-alpha1(I) type I collagen gene expression in the dermis after keloid excision and immediate intrawound injection of triamcinolone acetonide. J Am Acad Dermatol. 1997;37(4):586–9.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Sproat JE, Dalcin A, Weitauer N, Roberts RS. Hypertrophic sternal scars: silicone gel sheet versus Kenalog injection treatment. Plast Reconstr Surg. 1992;90(6):988–92.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Al-Attar A, Mess S, Thomassen JM, Kauffman CL, Davison SP. Keloid pathogenesis and treatment. Plast Reconstr Surg. 2006;117(1):286–300.CrossRefGoogle Scholar
  52. 52.
    Murray JC. Scars and keloids. Dermatol Clin. 1993;11(4):697–708.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Ledon JA, Savas J, Franca K, Chacon A, Nouri K. Intralesional treatment for keloids and hypertrophic scars: a review. Dermatol Surg. 2013;39(12):1745–57.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Shaffer JJ, Taylor SC, Cook-Bolden F. Keloidal scars: a review with a critical look at therapeutic options. J Am Acad Dermatol. 2002;46(2 Suppl Understanding):S63–97.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Jemec GB. Linear atrophy following intralesional steroid injections. J Dermatol Surg Oncol. 1988;14(1):88–9.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Mollmann H, Rohdewald P, Schmidt EW, Salomon V, Derendorf H. Pharmacokinetics of triamcinolone acetonide and its phosphate ester. Eur J Clin Pharmacol. 1985;29:85–9.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Meikle AW, Clarke DH, Tyler FH. Cushing syndrome form low doses of dexamethasone a result of slow plasma clearance. JAMA. 1976;235:1592–3.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Ross EJ, Linch DC. Cushing’s syndrome—killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet (London, England). 1982;2(8299):646–9.CrossRefGoogle Scholar
  59. 59.
    Marsden CW. Fluocinolone acetonide 0.25 cream-a co-operative clinical trial. Br J Dermatol. 1968;80:614–7.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Yi NW, Frame JD. Evaluation of cynthaskin and topical steroid in the treatment of hypertrophic scars and keloids. Eur J Plast Surg. 1996;19:162–5.Google Scholar
  61. 61.
    Hayashi T, Furukawa H, Oyama A, Funayama E, Saito A, Murao N, Yamamoto Y. A new uniform protocol of combined corticosteroid injections and ointment application reduces recurrence rates after surgical keloid/hypertrophic scar excision. Dermatol Surg. 2012;38:893–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Goldman L, Igelman JM, Kitzmiller KW. Clinical investigative studies with flurandrenolone tape. Cutis. 1967;3:367–71.Google Scholar
  63. 63.
    Rauscher GE, Kolmer WL. Treatment of recurrent earlobe keloids. Cutis. 1986;37:67–8.PubMedGoogle Scholar
  64. 64.
    Tillman WJ, Higuchi T. Quantitative evaluation of the interaction of callus strips with some hydroxylic solvents. J Invest Dermatol. 1961;27:87.CrossRefGoogle Scholar
  65. 65.
    Frank L, Rapp Y. Occlusive topical corticosteroids and heat in psoriasis. Arch Dermatol. 1963;87:32.PubMedCrossRefGoogle Scholar
  66. 66.
    Riley K. Flurandrenolone (Cordran) tape as occlusive therapy. JSC Med Assoc. 1969;65:171–2.Google Scholar
  67. 67.
    Fisher LB, Maibach HI, Trancik RJ. Effects of occlusive tape systems on the mitotic activity of epidermis with and without corticosteroids. Arch Dermatol. 1978;114:384–6.PubMedCrossRefGoogle Scholar
  68. 68.
    Widgerow AD, Chait LA, Stals R, et al. New innovations in scar management. Aesthetic Plast Surg. 2000;24:227–34.PubMedCrossRefGoogle Scholar
  69. 69.
    Goutos I, Ogawa R. Steroid tape: a promising adjunct to scar management. Scars, Burn Heal. 2017;3:2059513117690937.Google Scholar
  70. 70.
    Huang C, Akaishi S, Hyakusoku H, Ogawa R. Are keloid and hypertrophic scar different forms of the same disorder? A fibroproliferative skin disorder hypothesis based on keloid findings. Int Wound J. 2014;11(5):517–22.CrossRefGoogle Scholar
  71. 71.
    Huang C, Murphy GF, Akaishi S, Ogawa R. Keloids and hypertrophic scars: update and future directions. Plast Reconstr Surg Glob Open. 2013;1(4):e25.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Goldblatt S. The use of Cordran tape in dermatology. Ohio State Med J. 1969;65(11):1118–21.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Ratzer MA. A clinical trial of flurandrenolone tape. Br J Clin Pract. 1970;24:185–9.PubMedPubMedCentralGoogle Scholar
  74. 74.
    DP Study Group. Analysis of clinical outcomes of deprodone propionate plaster for various skin diseases. Rinsholyaku. 1989;5:2177–85. (in Japanese).Google Scholar
  75. 75.
    Labow TA, Eisert J, Sanders SL. Flurandrenolide tape in the treatment of psoriasis. NY State J Med. 1969;69:3138–40.Google Scholar
  76. 76.
    Kim S, Choi TH, Liu W, Ogawa R, Suh JS, Mustoe TA. Update on scar management: guidelines for treating Asian patients. Plast Reconstr Surg. 2013;132:1580.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Gold MH, Berman B, Clementoni MT, Gauglitz GG, Nahai F, Murcia C. Updated international clinical recommendations on scar management: part 1—evaluating the evidence. Dermatol Surg. 2014;40(8):817–24.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Gold MH, McGuire M, Mustoe TA, Pusic A, Sachdev M, Waibel J, et al. Updated international clinical recommendations on scar management: part 2—algorithms for scar prevention and treatment. Dermatol Surg. 2014;40(8):825–31.PubMedPubMedCentralGoogle Scholar
  79. 79.
    Meaume S, Le Pillouer-Prost A, Richert B, Roseeuw D, Vadoud J. Management of scars: updated practical guidelines and use of silicones. Eur J Dermatol. 2014;24(4):435–43.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Sclafani AP, Gordon L, Chadha M, Romo T 3rd. Prevention of earlobe keloid recurrence with postoperative corticosteroid injections versus radiation therapy: a randomized, prospective study and review of the literature. Dermatol Surg. 1996;22(6):569–74.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Layton AM, Yip J, Cunliffe WJ. A comparison of intralesional triamcinolone and cryosurgery in the treatment of acne keloids. Br J Dermatol. 1994;130:498–501.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Shah VV, Aldahan AS, Mlacker S, Alsaidan M, Samarkendy S, Nouri K. 5_Fluorouracil in the treatment of keloids and hypertrophic scars: a comprehensive review of the literature. Dermatol Ther. 2016;6:169–83.CrossRefGoogle Scholar
  83. 83.
    Saha AK, Mukhopadhyay M. A comparative clinical study on role of 5-fluorouracil versus triamcinolone in the treatment of keloids. Indian J Surg. 2012;74(4):326–9.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Prabhu A, et al. A randomized controlled trial comparing the efficacy of intralesional 5-fluorouracil versus triamcinolone acetonide in the treatment of keloids. J Sci Soc. 2012;39(1):19.Google Scholar
  85. 85.
    Khan MA, Bashir MM, Khan FA. Intralesional triamcinolone alone and in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. J Pak Med Assoc. 2014;64(9):1003–7.PubMedPubMedCentralGoogle Scholar
  86. 86.
    Darougheh A, Asilian A, Shariati F. Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. Clin Exp Dermatol. 2009;34(2):219–23.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Davison SP, Dayan JH, Clemens MW, Sonni S, Wang A, Crane A. Efficacy of intralesional 5-fluorouracil and triamcinolone in the treatment of keloids. Aesthet Surg J. 2009;29:40–6.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Manuskiatti W, Fitzpatrick RE. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585 nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol. 2002;138:1149–55.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Asilian A, Darougheh A, Shariati F. New combination of triamcinolone, 5-Fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatol Surg. 2006;32(7):907–15.PubMedPubMedCentralGoogle Scholar
  90. 90.
    Alster T. Laser scar revision: comparison study of 585-nm pulsed dye laser with and without intralesional corticosteroids. Dermatol Surg. 2003;29:25–9.PubMedGoogle Scholar
  91. 91.
    Waibel JS, Wulkan AJ, Shumaker PR. Treatment of hypertrophic scars using laser and laser assisted corticosteroid delivery. Lasers Surg Med. 2013;45(3):135–40.PubMedCrossRefGoogle Scholar
  92. 92.
    Martin MS, Collawn SS. Combination treatment of CO2 fractional laser, pulse dye laser and triamcinolone acetonide injection for refractory keloid scars on the upper back. J Cosmet Laser Ther. 2013;15(3):166–70.PubMedCrossRefGoogle Scholar
  93. 93.
    Son IP, Park KY, Kim B, et al. Pilot study of the efficacy of 578 nm copper bromide corporate laser combined with intralesional corticosteroid injection for treatment of keloids and hypertrophic scars. Ann Dermatol. 2014;26:156–61.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Royal London Hospital, Barts Health NHS TrustWhitechapelUK
  2. 2.Centre for Cutaneous ResearchBlizard Institute, Queen Mary University of LondonLondonUK

Personalised recommendations